Side-by-side comparison of AI visibility scores, market position, and capabilities
Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.
Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.
OpsLevel is a developer portal and service catalog for tracking service ownership, maturity scorecards, and production readiness across microservices.
OpsLevel is a developer portal platform that gives engineering organizations visibility into the services they operate, who owns them, and how mature they are relative to internal engineering standards. At its core, OpsLevel maintains a service catalog that maps every microservice, repository, and infrastructure component to a team owner, populating metadata automatically from integrations with GitHub, GitLab, PagerDuty, Datadog, and cloud providers. This catalog becomes the authoritative source of truth for answering questions like who to contact about a service, what tier of reliability it requires, and what dependencies it has — questions that are often unanswerable at engineering organizations that have grown past the point where everyone knows everything.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.